Thinking about cancer or dealing with cancer risk can be scary or overwhelming, but we believe that receiving information and resources is comforting, empowering, and lifesaving.
Although most prostate cancers can be slow growing, some prostate cancers can be more aggressive. These aggressive cancers can become resistant to standard hormone therapy and metastasize (spread) to areas beyond the prostate. Research shows a link between these aggressive prostate cancers and inherited mutations in BRCA2. Inherited mutations in BRCA1, ATM and CHEK2 may also be linked to aggressive prostate cancers.
Approximately 10% of men with a hormone-resistant, metastatic prostate cancer will test positive for one of these mutations. As a result, national guidelines are recommend genetic counseling and testing for all men with metastatic prostate cancer to determine whether or not they have an inherited genetic mutation that is relevant to their cancer.
Men with a BRCA or other mutation who develop prostate cancer may be offered more extensive treatment sooner than patients who do not have a known mutation. Men with metastatic prostate cancer that is castration-resistant (mCRPC) may qualify for treatment with a targeted therapy known as a PARP inhibitor.
Prostate cancer patients with certain inherited mutations may qualify for participation in clinical trials of targeted therapies. Many ongoing studies are specifically designed for mutation carriers with prostate cancer.
Men from families with a BRCA or other mutations should consider genetic testing to help them and their doctors to decide on the most appropriate surveillance strategies for prostate cancer and to determine best treatment if they develop the disease. Cancer genetics is rapidly changing, so men with prostate cancer should also consider seeking cutting-edge opinion from experts at major cancer centers.